Prime Medicine (PRME) Income from Continuing Operations (2021 - 2026)
Prime Medicine (PRME) posted Income from Continuing Operations of 228713000.0 for Q1 2026, down 381.22% on a QoQ basis from 47528000.0 in Q4 2025, and down 340.77% year-over-year from 94994257.48 in Q1 2025.
Prime Medicine (PRME) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Prime Medicine's Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 228713000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 340.77% year-over-year to 228713000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 453235000.0 (down 124.36% YoY) and the FY2025 annual result came in at 204204000.0, down 4.25% from the prior year.
- Income from Continuing Operations was 228713000.0 for Q1 2026 at Prime Medicine, down from 47528000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 23840000.0 in Q1 2022 and bottomed at 228713000.0 in Q1 2026.
- A 5-year average of 60056529.41 and a median of 47528000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 37.56% — and 2026, when it slumped 340.77%.
- Prime Medicine's Income from Continuing Operations stood at 39283000.0 in 2022, then plunged by 67.1% to 65643000.0 in 2023, then surged by 35.6% to 42276000.0 in 2024, then fell by 12.42% to 47528000.0 in 2025, then plunged by 381.22% to 228713000.0 in 2026.
- Business Quant data shows PRME's Income from Continuing Operations at 228713000.0 in Q1 2026, 47528000.0 in Q4 2025, and 124403000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Prime Medicine | 524.20 Mn | 524.20 Mn | - | -228.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -228.71 Mn |
| Dec 31, 2025 | -47.53 Mn |
| Sep 30, 2025 | -124.40 Mn |
| Jun 30, 2025 | -52.59 Mn |
| Mar 31, 2025 | -51.89 Mn |
| Dec 31, 2024 | -42.28 Mn |
| Sep 30, 2024 | -52.52 Mn |
| Jun 30, 2024 | -55.33 Mn |
| Mar 31, 2024 | -45.76 Mn |
| Dec 31, 2023 | -65.64 Mn |
| Sep 30, 2023 | -50.71 Mn |
| Jun 30, 2023 | -42.39 Mn |
| Mar 31, 2023 | -39.40 Mn |
| Dec 31, 2022 | -39.28 Mn |
| Sep 30, 2022 | -29.35 Mn |
| Jun 30, 2022 | -29.35 Mn |
| Mar 31, 2022 | -23.84 Mn |
| Dec 31, 2021 | -62.91 Mn |
| Sep 30, 2021 | -16.41 Mn |